Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Feb 05, 2008 | Ten Percent Owner | Open market or private purchase of non-derivative or derivative security | Form 4 | 1,999 | $10.25 | 461,134 | |
| Feb 05, 2008 | Director, Ten Percent Owner | Open market or private purchase of non-derivative or derivative security | Form 4 | 1,999 | $10.25 | 461,134 | |
| Jun 02, 2020 | Director | Open market or private purchase of non-derivative or derivative security | Form 4 | 2,000 | $12.65 | 23,612 | |
| Mar 20, 2015 | VP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 2,000 | -- | -- | |
| Aug 20, 2008 | Chief Operating Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 2,000 | $13.54 | 46,449 | |
| Aug 01, 2008 | Director, President & CEO | Open market or private sale of non-derivative or derivative security | Form 4 | 2,000 | $15.43 | 23,200 | |
| Feb 12, 2008 | Ten Percent Owner | Open market or private purchase of non-derivative or derivative security | Form 4 | 2,000 | $10.01 | 612,176 | |
| Feb 12, 2008 | Director, Ten Percent Owner | Open market or private purchase of non-derivative or derivative security | Form 4 | 2,000 | $10.01 | 612,176 | |
| Jun 27, 2007 | Ten Percent Owner | Open market or private purchase of non-derivative or derivative security | Form 4/A | 2,012 | $11.23 | 116,677 | |
| Jun 27, 2007 | Director, Ten Percent Owner | Open market or private purchase of non-derivative or derivative security | Form 4 | 2,012 | $11.23 | 116,677 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.